Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension
Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension
Submitted by
admin
on February 1, 2014 - 11:12am
Source:
FierceBiotech
News Tags:
PG324
ocular hypertension
glaucoma
Aerie Pharma
Headline:
Aerie Pharmaceuticals Initiates Phase 2b Study of PG324, a Novel Fixed-Combination Product to Treat Patients with Glaucoma or Ocular Hypertension
Do Not Allow Advertisers to Use My Personal information
